Arca
Skip to content

Advanced hepatocellular carcinoma

Drug research and approvals for advanced hepatocellular carcinoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 210 studies of advanced hepatocellular carcinoma are recruiting on ClinicalTrials.gov, and Health Canada has authorized 13 drug trials for it since 2013.

  • Recruiting worldwide: 210
  • Trials authorized in Canada: 13
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 210 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 13; search them all in Canada trials
Mar 21, 2025A randomized phase 2 study of casdozokitug in combination with toripalimab plus bevacizumab in participants with unresectable and/or locally advanced or…CASDOZOKITUG (SRF388 (CHS-388)) / AVASTIN (BEVACIZUMAB) / TORIPALIMABCoherus BioSciences, Inc.Ongoing
Feb 28, 2025A phase III, randomised, open-label, sponsor-blinded, multicentre study of rilvegostomig in combination with bevacizumab with or without tremelimumab as…IMJUDO / RILVEGOSTOMIG (AZD2936) / AVASTINAstraZeneca Pharmaceuticals LPOngoing
Dec 30, 2024A multicenter, open-label, first-in-human study of tyra-430 in advanced hepatocellular carcinoma and other solid tumors with activating fgf/fgfr pathway…TYRA-430TYRA BIOSCIENCES INC.Ongoing
Apr 4, 2023A phase 1/2 exploratory study of the tbl1 inhibitor, tegavivint (bc2059), in patients with advanced hepatocellular carcinomaTEGAVIVINT (BC2059) / PEMBROLIZUMABITERION THERAPEUTICSPending
May 2, 2022A phase 1/2, safety confirmation and double-blind, placebo-controlled, randomized study of relatlimab in combination with nivolumab and bevacizumab in…RELATLIMAB (BMS-986016) / OPDIVO / BEVACIZUMABBristol-Myers SquibbOngoing
Dec 24, 2021Phase IIa study of microbial ecosystem therapeutics (met-2 and met-4) to evaluate their effects on fecal microbiome in patients with advanced hepatocellular…MET-2 / MET-4NUBIYOTAPending
Apr 3, 2019A randomized, controlled phase 3 study of cabozantinib (xl184) in combination with atezolizumab versus sorafenib in subjects with advanced hepatocellular…CABOZANTINIB/ ATEZOLIZUMABExelixis, Inc.Ongoing
Jun 21, 2017Pembrolizumab and stereotactic radiotherapy combined in subjects with advanced hepatocellular carcinoma - a phase II study (pemrad)KEYTRUDAPRINCESS MARGARET CANCER CENTREOngoing
Feb 22, 2017A phase Ib study of pdr001 in combination with sorafenib in patients with advanced hepatocellular carcinoma (hcc)PDR001 / FLUDEOXYGLUCOSE 18F / TC99M-MDPNovartis Pharmaceuticals CorporationClosed
Jul 25, 2016An open-label multicenter phase 1 study to evaluate the safety, pharmacokinetics and pharmacodynamics of h3b-6527 in subjects with advanced hepatocellular…H3B-6527EisaiClosed

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.